[STUDY_ID_REMOVED] ¬†
¬†
Study¬†ID:¬†SKM16‚ÄêLYT‚ÄêMEL¬†
¬†
Title:  Randomized, ¬†Double‚Äêblinded,¬†Split‚Äêface ¬†Study¬†comparing ¬†the¬†Cosmetic¬†Efficacy¬†and¬†Tolerability ¬†
of¬†Two¬†Topical¬†Products¬†in¬†Subjects¬†with¬†Moderate ¬†Facial¬†Melasma¬†
 
 
Protocol¬†Amendment ¬†1¬†Date:¬†26¬†Oct¬†2016¬†
Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 1 of 29 
  Version Date: 26Oct16  
Randomized, Double-blinded, Split-face Study comparing the 
Cosmetic Efficacy and Tolerability of Two Topical Products 
in Subjects with Moderate Facial Melasma 
 
PROTOCOL NUMBER:  SKM16-LYT-MEL Amendment 1 
 
 
FUNDING SPONSOR:   SkinMedica Inc., an Allergan Company 
2525 Dupont Drive  
Irvine, CA 92612 
        
  
PRINCIPAL INVESTIGATOR:  
            
 
 
      
  
PROTOCOL DATE:   26/Oct/2016 
  
 
The study will be conducted according to  the protocol and in compliance with 
International Conference of Harmonisation Good Clinical Practice Guidelines and all 
other applicable regulat ory requirements. 
 
CONFIDENTIALITY STATEMENT 
THE INFORMATION PROVIDED  IN THIS STUDY PROTOCOL IS INTENDED FOR 
REVIEW BY THE PRINCIPAL INVESTIGATOR, ALL RESEARCH RELATED 
PERSONNEL, ETHICS COMMITTEE(S)  AND HEALTH AUTHORITIES. 
INFORMATION PROVIDED AND CAPTURED IN THIS PROTOCOL IS STRICTLY 
CONFIDENTIAL AND WILL ONLY BE DISCLOSED WITH WRITTEN CONSENT 
FROM THE SPONSORS. 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 2 of 29 
  Version Date: 26Oct16 PROTOCOL SIGNATURE PAGE 
 
Randomized, Double-blinded, Split-face Study comparing the 
Cosmetic Efficacy and Tolerability of Two Topical Products 
in Subjects with Moderate Facial Melasma  
 
PROTOCOL NUMBER:  SKM16-LYT-MEL Amendment 1 
 
 
FUNDING SPONSOR:   Skinmedica, Inc., An Allergan Company 
2525 Dupont Drive 
Irvine, CA 92612 
  
PRINCIPAL INVESTIGATOR:    
     
 
    
  
  
PROTOCOL DATE:   
26/Oct/2016  
 
 I,  agree to conduct protocol ‚ÄúRandomized, Investigator-
blinded, Split-face Study comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Subjects with  Moderate Facial Melasma‚Äù in accordance and 
compliance with International Conference of  Harmonisation Good C linical Practice 
Guidelines and all applicabl e regulatory requirements. 
   ACCEPTED AND AGREED:    Principal Investigator Sign ature:
   
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 3 of 29 
  Version Date: 26Oct16 Table of Contents 
STUDY SYNOPSIS ¬†............................................................................................................................... ¬†5¬†
1.0  BACKGROUND ¬†.............................................................................................................................. ¬†5¬†
2.0  STUDY OBJECTIVE ¬†...................................................................................................................... ¬†6¬†
3.0  STUDY POPULATION ¬†.................................................................................................................. ¬†6¬†
3.1 Inclusion Criteria ¬†.......................................................................................................................... ¬†6¬†
3.2 Exclusion Criteria ¬†......................................................................................................................... ¬†7¬†
4.0  METHODS AND MATERIALS ¬†...................................................................................................... ¬†9¬†
4.1 Study Products ¬†............................................................................................................................. ¬†9¬†
4.2 Subject Compliance ¬†.................................................................................................................. ¬†10¬†
4.3 Concomitant Medications ¬†......................................................................................................... ¬†10¬†
4.4 Treatment Group Randomization ¬†............................................................................................ ¬†10¬†
¬†
¬†
¬†
6.0 ASSESSMENTS ¬†............................................................................................................................ ¬†13¬†
6.1 Clinical Grading of Efficacy Parameters ¬†................................................................................ ¬†13¬†
6.2 Investigator‚Äôs Tolerability Assessment ¬†................................................................................... ¬†15¬†
6.3 Subject MELASQOL Assessmen t¬†........................................................................................... ¬†16
¬†
6.4 Subject Self-Assessment Questionnaires ¬†.............................................................................. ¬†16¬†
6.5 Imaging Procedures ¬†.................................................................................................................. ¬†16¬†
6.6¬† Mexameter Instrumentation Procedures ¬†.......................................................................... ¬†16¬†
7.0  STATISTICS ¬†.................................................................................................................................. ¬†17¬†
8.0 RESPONSIBILITIES OF THE INVESTIGATOR ¬†....................................................................... ¬†17¬†
8.1 Adherence to the Study Protocol ¬†............................................................................................ ¬†17¬†
8.2 Data Handling and Record Keeping ¬†....................................................................................... ¬†17¬†
9.0 REGULATORY OBLIGATIONS ¬†.................................................................................................. ¬†17¬†
9.1 Institutional Review Board ¬†........................................................................................................ ¬†17¬†
9.2 Protocol ¬†....................................................................................................................................... ¬†18¬†
9.3 Informed Consent¬† ...................................................................................................................... ¬†18¬†
9.4 Protocol and Informed Consent Changes ¬†.............................................................................. ¬†18¬†

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 4 of 29 
  Version Date: 26Oct16 9.5 Study Monitoring ¬†........................................................................................................................ ¬†18¬†
10.0 CONFIDENTIALITY OF RECORDS ¬†........................................................................................ ¬†19¬†
11.0 DELEGATION OF INVESTIGATOR RESPONSIBILITIES ¬†................................................... ¬†19¬†
12.0 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS ¬†........................................................ ¬†19¬†
13.0 ADVERSE EVENTS AND REPORTING ¬†................................................................................. ¬†19¬†
13.1 Serious And/Or Adverse Event Reporting¬† ........................................................................... ¬†19¬†
13.2 Pregnancy During The Study ¬†................................................................................................ ¬†21¬†
13.3 Anticipated Reactions ¬†............................................................................................................. ¬†21¬†
13.4 Unknown/Unforeseeable Risks ¬†............................................................................................. ¬†21¬†
13.5 Unblinding ¬†................................................................................................................................. ¬†22¬†
14.0¬† REFERENCES ¬†......................................................................................................................... ¬†22¬†
¬†
¬†
 
 
  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 5 of 29 
  Version Date: 26Oct16 STUDY SYNOPSIS 
 
Protocol Number  
SKM16-LYT-MEL Amendment 1 
Protocol Title Randomized, Double-blinded, Split -face Study comparing the 
Cosmetic Efficacy and Tolerability of Two Topical Products in 
Subjects with Moderate Facial Melasma
Study Duration 3 months (12 Weeks )
Study Population 20 health y subjects with Fitzpatrick Skin T ypes III-VI 
Objectives To evaluate and compare the ef ficacy and tolerability of two 
topical products in the improv ement of facial melasma  
Study Design Single site, investigator-initi ated, double-blinded, parallel arm, 
randomized treatment, split-face,  12-week study comparing the 
efficacy and tolerability of SkinMedica‚Äôs cosmetic topical brightener versus generic hydroqui none 4% topical prescription 
cream. A total of 20 healthy subjects will be enrolled into this 
study. Subjects will be screened and randomized at Baseline and 
will return for visits at Weeks 4, 8 and 12. The test products will 
be applied only to the affected areas  (dark patches) twice a day, 
morning and evening, every day for 12 weeks. Ancillary products will be provided fo
rbasic dail y skincare re gimen use. 
Study Products ÔÇ∑ SkinMedica Facial Cleanser 
ÔÇ∑ SkinMedica Rejuvenative Moisturizer 
ÔÇ∑ SkinMedica Essential Defense Mineral Shield Broad 
Spectrum SPF 35 Sunscreen 
ÔÇ∑ Test Product A (Lytera 2.0) ÔÇ∑ Test Product B 
(4% H ydroquinone Topical Cream ) 
Eligibility Criteria Subjects aged 18+  
with s ymmetrical moderate facial melasma. 
 
 
1.0  BACKGROUND 
 Melasma is a common disorder of hyperpigm entation which typically presents as brown 
or grayish brown macules on the face, in cluding the forehead, malar region, upper lip 
and chin. Melasma is commonly observed in wo men with Fitzpatrick skin types III to V 
(1), especially Asian and Hispanic women, although all skin types can be affected.   
 Contributing causes of melasma may include ultraviolet irradi ation, oral contraceptives, 
hormone replacement therapy, pregnancy, and thyroid dysfunction (2) however the exact etiology are not yet fully understood.  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 6 of 29 
  Version Date: 26Oct16 Many patients find the uneven skin t one appearance caused by melasma to be 
cosmetically unacceptable.  Finding a succe ssful treatment remains challenging and 
frustrating. Therapies include broad-spectrum sunscreens, hy droquinone, tretinoin, kojic 
acid, alpha hydroxy acids, salicy lic acid, and chemical peels.  
 
The treatment of hyperpigmentation a ssociated with skin aging and melasma is 
challenging due to the prolonge d time to respond and its high relapse rate when therapy 
is discontinued.  Patients are also required to avoid sunlight to improve therapeutic 
results. Hydroquinone is cu rrently the gold standard for the topical treatment of 
hyperpigmentation and melasma.  
2.0  STUDY OBJECTIVE 
 The objective of this study is to evaluate the efficacy and tolerability of SkinMedica‚Äôs 
cosmetic topical brightener versus 4% hydroquinone in the improvement of the 
appearance of moderate facial melasma over the course of 12 weeks. 
 
3.0  STUDY POPULATION 
 Twenty (20) healthy subjects presenting wit h symmetrical moderate facial melasma, 
who meet all inclusion and exclusion criteria will be eligible to participate in this study. 
 3.1 Inclusion Criteria 
A subject will be eligible to participate if they meet all of the following inclusion 
criteria: 
 
1. Female or male aged 18+ years  
 
 
2. Individuals with symmetrical  (with at least left and right malar region involvement) 
moderate melasma  
. 
 
3. Individuals that are willi ng to provide written informed consent and are able to 
read, speak, write, an d understand English.  
 
4. Individuals willing to sign a photography release. 
 
5. Willing to withhold all facial treatments during the course of the study including 
botulinum toxin, injectable fi llers, microdermabrasion, IP L, peels, facials, waxing, 
laser treatments and tightening treatments.  Threading is allowed but not facial 
laser hair removal. 
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 7 of 29 
  Version Date: 26Oct16 6. Willingness to cooperate and participate by  following study requirements  for the 
duration of the study and to report any c hanges in health status  or medications, 
adverse event symptoms, or  reactions immediately. 
 
7. Willingness to not begin using any new co smetic facial make-up during the study. 
If regular users of cosmetic facial make- up, they must have used the product(s) 
without any tolerability issues for at least 2 weeks prior to starting the study. 
 
8. Willingness to avoid as much as possi ble, direct and prolonged sun exposure for 
the duration of the study (including t anning beds), especially from 10 AM to 2 
PM. Subjects are asked to wear protecti ve clothing prior to and during exposure.  
Any extended sun exposure must be recorded in the source documents. 
 
3.2 Exclusion Criteria 
A subject will not be eligible to participat e if they meet an y of the following 
exclusion criteria. 
 
1. Individuals diagnosed with known allergies to study provided skin care products. 
 
2. Individuals who are nu rsing, pregnant, or planning to become pregnant during 
the study according to subject self-report. 
 
3. Individuals with a hi story of skin cancer. 
 
4. Individuals having a health condition and/ or pre-existing or dormant dermatologic 
disease on the face (e.g., psoriasis,  rosacea, acne, eczema, seborrheic 
dermatitis, severe excori ations etc.) that the In vestigator or designee deems 
inappropriate for participation or could in terfere with the outcome of the study. 
 
5. Individuals with a hist ory of immunosuppression/immune deficiency disorders 
(including (HIV infection or AIDS) or currently using immunosuppressive 
medications (e.g., azathioprine, belim umab, cyclophosphamide, Enbrel, Imuran, 
Humira, mycophenolate mofetil, methotre xate, prednisone, Remicade, Stelara.) 
and/or radiation as determined by study doc umentation that the Investigator or 
designee deems inappropriate for participation or could interfere with the 
outcome of the study. 
 
6. Individuals with an uncontro lled disease such as asthma, diabetes, hypertension, 
hyperthyroidism, or hypothyro idism. Individuals having mu ltiple health conditions 
may be excluded from participatio n even if   the conditions are controlled by diet, 
medication, etc. 
 
7. Individuals with any planned surgeries and/or invasive medical procedures during 
the course of the study. 
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 8 of 29 
  Version Date: 26Oct16 8. Individuals who are current ly participating in any other facial usage study or have 
participated in any clinical trial within 4 weeks prior to inclusion into the study. 
 
9. Individuals who have observable suntan, sca rs, nevi, excessive hair, etc. or other 
dermal conditions on the face that might in fluence the test results in the opinion 
of the Investigator or designee. 
 
10. Individuals who start ed hormone replacement therapi es (HRT) or hormones for 
birth control less than 3 months prior to  study entry or who plan on starting, 
stopping, or changing doses of HRT or hormones for birth control during the 
study. 
 
11. Individuals who used any of the following medications or had any of the listed 
procedures within the listed time fram e prior to the study start date: 
ÔÇ∑ Retin-A¬Æ, Retin-A Micro¬Æ, Renova¬Æ , Avita¬Æ, Tazorac¬Æ, or Differin¬Æ 
within 3 months 
ÔÇ∑ Had a light-depth chem ical peel or microderm abrasion within 1 month 
ÔÇ∑ Had a medium-depth chemical peel , medium-depth microdermabrasion, 
any systemic steroids, non-ablative lase r, light and/or radio frequency or 
fractional laser resurfacing of the face and neck within 3 months 
ÔÇ∑ Any systemic retinoid (e.g. Soriat ane¬Æ, Accutane¬Æ, Roche Dermatologics) 
within 12 months   
ÔÇ∑ Any topical or systemic antibiotics, such as minocycline, or any other 
known medications that can cause photosensitivity, such as 
hydrochlorothiazide, lasix, amiodarone, within 1 month 
ÔÇ∑ Any topical tretinoin product or deriv ative, imiquimod, 5-fluorouracil, or 
diclofenac on their face within 3 months 
ÔÇ∑ Prescription strength skin lightening products (e.g. 4% hydroquinone, 
tretinoin, AHA, BHA and polyhydroxy acids, 15% or 20% azelaic acid, 4-
hydroxyanisole alone or in combinati on with tretinoin, et c.) within 3 months 
ÔÇ∑ Any non-prescription cosmetic anti-wr inkle, skin lightening products, or 
any other product or topical or system ic medication known to affect skin 
aging or dyshcromia (products containing alpha/beta/poly- hydroxy acids, 
vitamin C, soy, Q-10, hydroquinone; syst emic or licorice extract (topically), 
Tego¬Æ Cosmo C250, gigawhite, lemon juice extract (topically), emblica extract, etc.) within 2 weeks 
ÔÇ∑ Have undergone plastic surgery, Dermabrasion (deep skin peel), a deep 
chemical peel or ablative laser resu rfacing of the face and neck within 12 
months 
ÔÇ∑ Had facial treatment with a botulin um toxin base injectable (Botox), 
injectable fillers, or a fat transfer within 6 months 
 
 
 

3URWRFRO6.0/<70(/  6SRQVRU6NLQ 0HGLFD,QF
3DJHRI
  9HUVLRQ'DWH2FW0(7+2'6$1'0$7(5,$/6
6WXG\3URGXFWV
SkinMedica Facial Cleanser: Water/Aqua/Eau,Disodium Laureth 
Sulfosuccinate,Cocamidopropyl Hydroxysultaine,Sodium Lauryl 
Sulfoacetate,Camellia Oleifera Leaf Extract, Glycerin, Panthenol, Butylene Glycol, Ethylhexylglycerin,PEG-150 Pentaerythrityl Tetrastearate, PEG-6, 
Caprylic/Capric, Glycerides, Disodium EDTA, Phenoxyethanol, 
Parfum/Fragrance, Blue 1 (CI 42090), Yellow 10 (CI 47005)  Test Product A (Cosmetic topical serum ‚ÄúLytera 2.0‚Äù): Water/Aqua/Eau, Butylene 
Glycol, Glycerin, Niacinamide, Polyacrylate-13,  Phenylethyl Resorcinol, Tranexamic Acid, Vitis Vinifera (Grape) Flower Cell Extract, Plankton Extract, Tetrapeptide-30, Artemisia Capillaris Flower Extract, Vibrio Alginolyticus Ferment Filtrate, Alteromonas Ferment Extract, Tocopheryl Acetate, Polyisobutene, Polysorbate 20, Caprylic/Capric Triglyceride, Hydroxyacetophenone, Phytic Acid, Diethylhexyl Syringylidenemalonate, Disodium EDTA, Ethylhexylglycerin, Phenoxyethanol   SkinMedica Rejuvenative Moisturizer: Water/Aqua/Eau, Caprylic/Capric 
Triglyceride, Tocopheryl Acetate, Diglycerin, Isostearyl Behenate, Glyceryl Stearate, PEG-100 Stearate, Tetrahexyldecyl Ascorbate, Butyrospermum Parkii Butter, Panthenol, Phytosterols, Tocopherol, Tocotrienols, Squalene, Oryza Sativa Bran Cera, Aloe Barbadensis Leaf Juice, Algae Extract, Bisabolol, Ginkgo Biloba Leaf Extract, Avena Sativa Kernel Extract, Sodium Hyaluronate, Stearyl Glycyrrhetinate, Retinyl Palmitate, Glycerin, Glyceryl Polyacrylate, Dimethicone, Cetyl Alcohol, Cetearyl Alcohol, Ceteareth-20, Caprylyl Methicone, Carbomer, Tromethamine, Disodium EDTA , Potassium Sorbate, Phenoxyethanol, Ethylhexylglycerin, Parfum/Fragrance   SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 
Sunscreen: Water, Cyclopentasiloxane, Dimethicone, Polyglyceryl-3 
Polydimethylsiloxyethyl Dimethicone, Butylene Glycol, Aluminum Hydroxide, Dimethicone/PEG-10/15 Crosspolymer, PEG-9 Polydimethylsiloxyethyl Dimethicone, Sodium Chloride, Caffeine, Camellia oleifera Leaf Extract, Sodium Citrate, Dimethicone/Vinyl Dimethicone Crosspolymer, Triethoxysilylethyl Polydimethylsiloxyethyl Hexyl Dimethicone, Stearic Acid, Ethylhexylglycerin, Phenoxyethanol  Test Product B (4% Hydroquinone Topical Prescription Cream): 
 [Ingredients TBD depending on Pharmacy] (y q p
[Ingredients TBD depending on Pharmacy]
Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 10 of 29 
  Version Date: 26Oct16 4.2 Subject Compliance  
Subject compliance to the study treatment r egimen will be verbally assessed; 
study personnel will ask each subject whether they missed any applications of 
study treatment since the previous vi sit and will quantify the subject‚Äôs response.  
 
4.3 Concomitant Medications 
Systemic and topical medications being us ed at baseline that are considered 
necessary for the subject‚Äôs welfare and will not interfere with the study may be 
used.  Administration of these drugs mu st be reported on the appropriate case 
report form and any alterations in the us e of the medication during the study will 
be carefully noted.  Administra tion of a prohibited drug ( see section 4.2 of 
protocol) in an emergency situation is done with the safety of the study 
participant as the prime consideration.  All topical and systemic medications that 
the subject receives during the study will be recorded.  Any alterations will be 
noted. 
  
4.4 Treatment Group Randomization 
Subjects will be randomized in a 1:1 fashion to receive treatment with 
SkinMedica‚Äôs cosmetic topical bright ener or 4% hydroquinon e. A randomization 
table will be provided by the sponsor and used to determine which facial side will 
be treated with Test Product A (cosmetic topical serum ‚ÄúLytera 2.0‚Äù) and Test 
Product B (4% hydroquinone)  for each subject.  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
Page 11 of 29 
  Version Date: 26Oct16  
 
 
 
  
   
  
  
  
  
 
 
   
  
  
  
  
  
  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 12 of 29 
  Version Date: 26Oct16 ÔÇ∑ Randomization and distribution of study products by the Unbl inded study staff 
   
 
 
 
 
 
 
 
 
  
 
  
  
 
  
  
     
 
 
 
  
 
  
  
 
  
  
     
 
 
 
  
   

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 13 of 29 
.  Version Date: 26Oct16   
  
  
   
  
  
  
  
  
    
 
 
 
 
6.0 ASSESSMENTS  
 6.1 Clinical Grad
ing of Efficacy Parameters  
 
Clinical grading of the efficacy parameter will be performed at t he study visits indicated. 
Hyperpigmentation will be assessed on the left and the right side  of each subject‚Äôs 
face separately. 
 
Melasma Severity Rating Scale: 
At the screening/baseline visit and the end of treatment visit (week 12), the 
Invesgator will assess the subject‚Äôs facial  skin for the severity of symmetrical 
facial melasma using the following Mela sma Severity Rating Scale on the left and 
right facial sides. Subjects must present with a score of 2 for the left and the right 
facial sides to be enrolled into the study. 
Score H yperpi gmentation Status
0 Cleared: color of melasma lesions 
approximately equivalent to 
surrounding normal skin or with minimal residual h
yperpi gmentation
1 Mild: color slightly darker than the 
surroundin g normal skin
2 Moderate: color moderately darker 
than the surroundin g normal skin
3 Severe: color markedly darker than 
the surroundin g normal skin
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 14 of 29 
  Version Date: 26Oct16 Overall Hyperpigmentation Scale: 
At all visits (baseline, weeks 4, 8 and 12) , the Investigator will globally assess the 
subject‚Äôs left and right facial sides fo r overall hyperpigm entation using the 
following ten point scale (0 ‚Äì 9): 
None  
(Score of 0)  
Skin is normal in color with no evidence of hyperpigmentation  
Mild  
(Score of 1, 2 or 3) Several brown spots with increas ed pigmentation; they are 
small in size and slightly darker than surrounding skin 
Moderate  
(Score of 4, 5 or 6) Many brown spots with increas ed pigmentation; they are 
medium in size and much darker than surrounding skin 
Severe  
(Score of 7, 8 or 9) Many large brown spots with increased pigmentation; they 
are large in size and markedly darker than surrounding skin
 
 
Half-face Evaluation of Melasma Area Severity Index (MASI) Score 
At all visits, (baseline, weeks 4, 8 and 12), the Investigator will assign a grade for 
the left and right facial sides, for each of the below units, for the variable A 
(percentage of each area involved), D (dar kness of pigment) and P (pattern of 
involvement), as described in detail below.   
Calculations will be conducted by the s ponsor upon receipt of the completed 
CRFs. 
3 variables are assessed for each half- facial unit : 
- Total Area Involved ( A) 
- Darkness of pigment ( D)  
- Homogeneity ( H) 
 
Variable Definitions: 
A = A numerical value is assigned for th e corresponding percentage of the 
total area of the facial segment being assessed.   
This value represents ONLY the percent of the area invo lved, not the pattern or 
darkness of the pigment.  
0=  No involvement 
1= <10% involvement 
2= 10-29% involvement 
3= 30-49% involvement 
4= 50-69% involvement 
5= 70-89% involvement 
6= 90-100% involvement  
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 15 of 29 
  Version Date: 26Oct16 D = Darkness of the pigment compared to adjacent normal pigment.   
0= Normal skin color  
1= Slightly darker than normal color 
2 = Mild hyperpigmentation 
3= Modrate hyperpigmentation,clearl y and distinctly darker than normal 
pigment 
4 = Severe hyperpigmentation, virtually black pigment  
 
H = The homogeneity of the pigmentation will be assessed using the below 
scale:  
0= Normal skin color without evidence of hyperpigmentation 
1= Specks of involvement  
2 = Small patchy areas of in volvement < 1.5 cm diameter   
3 = Patches of involvement> 2 cm diameter   
4 = Uniform skin involvement  without any clear areas  
 
Calculation of the hal f-face MASI score:  
To calculate the half-face MASI score, t he sum of the severity grade for darkness 
(D) and homogeneity (H) is multiplied by t he numerical value of the areas (A) 
involved and by the percentages of the four facial areas (10-30%). 
 
Total Half-Face MASI score:  
Half Forehead 0.15(D+H)A + One Mala r Side 0.3 (D+H)A + Half Chin 
0.05(D+H)A 
 
 
Investigator‚Äôs Global Improvement Assessment- Overall 
Hyperpigmentation: 
 
The expert grader will also score an In vestigator‚Äôs Global Improvement 
Assessment for Overall Hyperpigmentation on the left and right facial sides at all 
follow-up visits (weeks 4, 8, and 12). 
0=No change or worsening 
1=Mild improvement (~25% overall improvement) 2=Moderate improvement (~50% overall improvement) 3=Marked improvement (~75%  overall improvement) 
4=Complete clearing/Dramatic improv ement (~95%+ overa ll improvement) 
 
6.2 Investigator‚Äôs Tolerability Assessment 
Tolerability of the test pr oducts will be assessed through the capture of adverse events 
reported throughout the study per iod. Any adverse event(s) ex perienced by the subject 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 16 of 29 
  Version Date: 26Oct16 during the study period, whether  related to the treatment or  not, will be recorded in the 
‚ÄúCase Report Form.‚Äù 
6.3 Subject MELASQOL Assessment  
Subjects will complete the MELASQOL assessement regarding their full face at the 
baseline visit and their left and right facial sides at week 12. The MELASQOL is a 
validated assessment to help measure the emotional and psychological impact of 
melasma (3).  This questionnaire is found in   
 6.4 Subject Self-Assessment Questionnaires  Subjects will complete a Sponsor-provided se
lf-assessment questionnaire at follow-up 
visits at weeks 4, 8, and 12. The assessment consists in a personal and subjective evaluation of their facial skin quality on the left and right side during and after the 
treatment by the subject. In  addition, the assessment serves to evaluate the self-
perceived cosmetic efficacy of the treat ment and the product attributes. This 
questionnaire is f ound in  
 6.5 Imaging Procedures Photograp
hs will be taken at all visits utilizing standardized conditions for all subjects.  
The skin must be cleansed prior to photography to remove any makeup, including foundation makeup, lipstick/ gloss and eye shadow. The settings for the exposure, 
lighting, flash, and focal length will be maintained constant over the course of the study.  
 Ensure that subjects jewelry is remov ed from ears/neck and hair is pushed back away 
from the face, ensuring that no stray hairs are in the facial area. Subjects will be photographed using an appropriate  clinical digital photography system 
 at highest resolution in a 
consistent position. Importantly, the phot ography should be taken to enable comparison 
of baseline photos with later photos taken at the end of the treatment period. For 
instance, if available, the overlay functi on must be used. As each photograph is being 
taken, it should be viewed to ensure that it is in focus and is similar to its baseline 
counterpart in all technical aspects, includi ng lighting, distance and angle. In addition, 
the face should be captured in neutral faci al expressions and neutral angles (e.g., 
avoiding hypo- or hyperex tension of the neck).  
 Photos using the  will be taken from three angles to enable the improvement to 
be clearly noticed: full frontal (0 ¬∞) and at profile from the left (45¬∞) and from the right side 
(45¬∞). Photos will be taken at controlled di stances under standard r oom lighting. Cross-
polarized, parallel- polarized and visible light images will be acquired along with both 
blue fluorescence and ultraviolet fluore scence images. During the photography, the 
subjects will be asked to keep their eyes closed. 
 
6.6 Mexameter Instrume ntation Procedures 
Two target hyperpigmented lesi ons will be selected from the left (1) and the right (2) 
malar facial areas and measured by the mexameter, and instrument that measures 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 17 of 29 
  Version Date: 26Oct16 melanin content. Measurement s at subsequent visits must  be taken from the same 
target lesion locations as at the baseline visit within each subject. 
One target ‚Äúnormal‚Äù measur ement will also be taken from an unaffected skin area on 
the face representing normal skin. The values  from the target hyperpigmented lesions 
will be compared to the normal lesion value. 
 
7.0  STATISTICS 
Statistical analyses will be c onducted by the sponsor on an in tent-to-treat basis (ex: all 
enrolled subjects, with at least one follow- up visit, will be included in the analysis).   
 
8.0 RESPONSIBILITIES OF THE INVESTIGATOR 
8.1 Adherence to th e Study Protocol 
The Investigator must ensure adherence to  the procedures outlined in this Study 
Protocol.  The procedures set out in this study protocol, pertaining to the conduct, 
evaluation, and documentation of this st udy, are designed to ensure that the 
Investigator abides by GCP as descri bed in the ICH Guidelines Topic E6: 
‚ÄúGuideline for Good Clinical Practice.‚Äù  Compliance with these regulations also 
constitutes compliance with the ethical prin ciples described in the current revision 
of the Declaration of Helsinki.  The st udy will also be carried out in keeping with 
local legal and regulat ory requirements. 
 
8.2 Data Handling and Record Keeping 
The Investigator must ensure that pr oper source documentation for all study 
activities are diligently maintained and securely kept.  The Investigator will 
transfer all relevant data to the Case Report Form as stipulated in this Study 
Protocol and his/her signature on the Case Report Form guarantees completeness and integrity of these data.  The Investigator will store all study 
related supplies in a secure and locked loca tion. In addition, the Investigator will 
ensure that all Case Report Forms will be maintained for a period of two years 
after the conclusion of the study. 
 
9.0 REGULATORY OBLIGATIONS 
9.1 Institutional Review Board 
The study protocol, informed consent fo rms (all versions), and any specific 
advertising will be submitted to and approved by Independent Investigational 
Review Board before the start of the study.  A form must be signed by the 
chairman or designee of the IRB noting the approvals. This notification will be provided to SkinMedica for notif ication of study initiation. 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 18 of 29 
  Version Date: 26Oct16 9.2 Protocol 
The Investigator signing the protocol signature page will act as the Principal 
Investigator at this site. Protocols wil l be noted as approved by the Investigator 
by placement of his signature on the Invest igator‚Äôs Signature Page.  Copies of 
the IRB approved protocol and informed consents will be provided to 
SkinMedica. 
 
9.3 Informed Con sent 
An Informed Consent Form (ICF) that in cludes all of the relevant elements 
currently required by FDA or stat e regulations will be provided to each 
prospective study subject at screening and before enrollment into  the study.  The 
type and method of study, any potential or possible hazards, and the subject‚Äôs 
right to withdraw from the study at any time will be explained to the subjects by 
the Investigator or Designee. Once the In vestigator or Designee is assured that 
an individual candidate understands  the implications of participating in this study, 
the subject will be asked to give consent  by signing and dating in the appropriate 
areas of the Informed Consent Form.  The Investigator or Designee will also sign 
and date the ICF.  A copy of the IRB appr oved ICF will be given to the subject for 
the subject‚Äôs records and the original will be filed in the subject‚Äôs binder or folder. 
 
9.4 Protocol and Informed Consent Changes Changes to the protocol or Informed Consent Forms will be implemented as 
amendments to the original document and approved by the IRB.  The approvals 
will be processed in accordance with the established IRB procedures.  Copies of 
all protocol and ICF amendments/revi sions, along with letters noting IRB 
approval, will be submitted to SkinMedica , as this may affect safety.  Any 
addenda, amendment or revision that substantially alte rs the study design or 
increases potential risk to the subjec t will require the subject‚Äôs consent to 
continue in the study. 
 
9.5 Study Monitoring 
The site will be responsible for internal ve rification of complete  and accurate data 
collection and confirming adherence to the protocol throughout the study. The 
study may be monitored by Sponsor repres entatives to ensure that the protocol 
and GCP guidelines are being followed and to assist in resolving any difficulties 
encountered while the study is in progress.  The monitoring may include site visits 
and frequent communications (telephone, fax, email, letters).  
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 19 of 29 
  Version Date: 26Oct16 10.0 CONFIDENTIALITY OF RECORDS 
 
Information about the subject‚Äô s health taken during this study may be used and given to 
others by the study coordinator s, the medical staff, the res pective study center and by 
the subject‚Äôs doctors and their other healthcare providers. The subject‚Äôs doctors and 
their healthcare providers may share health  information about the subject with the 
investigator and study coordi nator. The study coordinator and the providers may share 
that information with researchers participating in this study‚Äôs laboratories conducting 
tests for this study. A final study report ma y be shared with SkinMedica, Inc.; The U.S. 
Food and Drug Administration (FDA); Depart ment of Health and Human Services 
(DHHS) agencies; other U.S. and foreign government agencies that watch over quality, 
safety and effectiveness of research. 
 
All research related personnel will ensure su bject confidentiality is maintained. All 
subject related documents will be identified by subject initials and subject identification 
numbers. All subject related documents will be filed in individual subject binders or 
folders and stored in confidenc e by the site only to be accessed by research related 
personnel. 
 
11.0 DELEGATION OF INVESTIGATOR RESPONSIBILITIES 
 
The Investigator should ensure that all per sons assisting with the trial are adequately 
informed about the protocol, any amendments to  the protocol, the study treatments, and 
their trial-related duties and functions.  The investigator should maintain a list of sub-
investigators and other appropriately qualif ied persons to whom he has delegated 
significant trial-related duties.  
12.0 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS 
 
The Investigator must ensure that institutional regulations , the Informed Consent Form, 
and the HIPAA Authorization clearly permit st udy-related monitoring, audits, IRB review, 
and regulatory inspections providing direct access to source data and documents. 
 
13.0 ADVERSE EVENTS AND REPORTING 
 
13.1 Serious And/Or Adverse Event Reporting 
A serious adverse event is any untoward medical occurrence, that, at any dose: 
ÔÇß results in death; 
ÔÇß is life-threatening; 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 20 of 29 
  Version Date: 26Oct16 ÔÇß requires in-subject hospitalization or pr olongation of existing hospitalization; 
ÔÇß results in persistent or significant disability/incapacity;  
ÔÇß is a congenital anomaly/birth defect; or 
ÔÇß is an important medical event. 
 
Throughout the study, subjec ts will be monitored for signs and symptoms of 
adverse events.  An adverse event is any pathological or unintended change in 
the structure, function or chemistry of the body that  occurs during the study, 
irrespective of causality, including any ill ness, injury, toxicity, sensitivity, or 
sudden death.  The condition must eit her not be present pre-study or must 
worsen in either intensity or frequency during the study. 
 
An unanticipated adverse study drug event is any drug-related adverse event, 
which is not identified in nature, severity , or frequency in current literature on the 
test article.  
All adverse events, including serious and study drug related or unanticipated 
adverse drug events, must be recorded and assessed by th e Investigator.  In the 
event of an adverse event, serious adverse  event or unanticipated adverse drug 
event, the physician will prov ide optimal subject care. 
 
Subjects who have had a serious adverse event must be followed clinically until 
all parameters, including labor atory values, have either returned to normal or are 
otherwise explained.  
Any serious adverse event or unanticipat ed adverse drug event occurring in this 
study will be analyzed and identif ied by the investigator and reported to the IRB 
within 10 business days, as per IND regulations and FDA Guidance. The 
investigator will also determine the event re lated to the study drug and report that 
event to the manufacture of the device, if necessary. 
 
Serious adverse events will be reported to the Sponsor within 24 hours (or the 
next working day). The main Sponsor c ontact for serious adverse events is: 
 
 
 
 
 If death was the outcome of the event  on the initial SAE Report, a Follow-
up/Final Report, including autopsy report, when performed, must be completed. 
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 21 of 29 
  Version Date: 26Oct16 13.2 Pregnancy During The Study 
If a subject of childbearing potential becomes pregnant at any time while 
participating during the study, the pregnancy will be deemed an Adverse Event 
and the subject will stop all protocol related procedures. The investigator will 
follow-up with the subject until the pregnancy reaches term or until the pregnancy has been resolved. 
 
The Investigator will report the Adverse Event of pregnancy to the IRB within 24 
hours of awareness of the event and follow-up reports will be filed with the IRB 
as information with changes of t he pregnancy becomes available. 
 
13.3 Anticipated Reactions 
All test materials have the potential to cause some minor side-effects or other 
reactions. Possible reactions to the test  material(s) may include (but are not 
limited to) subjective sensations (such as itching, burning, stinging, tingling), scaling/dryness, and redness. Additionally, test materi al(s) applied to the eye 
areas have the potential to cause eye wa tering/tearing, redness of the eyes, 
corneal erosions, and foreign body sensation in the eyes.   Symptoms of mild to moderate irritation, including the examples discussed above, will not be treated as adverse reactions if they ar e mild in nature. These 
conditions may or may not resolve over ti me. Symptoms that are persistent and 
moderate to severe in natur e, or that involve elevat ion (e.g. edema, papules, 
vesicles, spreading) wil l be considered AEs.  
In rare cases, it is possible for a subject to develop allergic reactions to the test 
material(s). This risk is increased for i ndividuals with a history of allergies, and 
individuals with asthma and/or  a history of hives may al so be affected. Subjects 
will be instructed to notify the clinic imm ediately if they experience an allergic 
reaction including rash, hives, and itching.  The Investigator or designee will have the final authorization to determine if a reaction will be c onsidered an AE.  
 
13.4 Unknown/Unforeseeable Risks 
In addition to the risks listed above, t here may be some unknown or infrequent 
and unforeseeable risks associated with the use of the assigned study products. 
Subjects will be informed both verbally and in writing in a timely manner of any 
new information, findings or changes to the way the research will be performed that might influence their willingness to cont inue their participation in this study. 
 Pregnancy/Fetal Risks:  The effects of SkinMedica Facial Cleanser, Rejuvenative Moisturizer, Essential Defense Mineral Shield Broad Spectrum SPF 35, Test 
Product A (Lytera 2.0) and Test Produc t B (4% Hydroquinone) have not been 
studied in pregnancy and theref ore may be hazardous.   
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 22 of 29 
  Version Date: 26Oct16 If a subject thinks that she may be pr egnant or have become pregnant during the 
study she is to inform the study docto r immediately. If a subject becomes 
pregnant or thinks they may be pregnant, t hey will be removed from the study 
and the study doctor will refer the subject to seek obstetric care and may request 
to track their pregnancy and will report  to the IRB. 
 
13.5 Unblinding 
In the event that a subject experiences  an Adverse Event or Serious Adverse 
Event, the Investigator and/or S ub-Investigator will become unblinded. 
 
14.0 REFERENCES 
1. Melasma: a clinical and epidemiologi cal review* Ana Carolina Handel, Luciane 
Donida Bartoli Miot, and H√©lio Amante Mio t, An Bras Dermatol. 2014 Sep-Oct; 
89(5): 771‚Äì782. 
2. Melasma. Etiologic and Therapeutic Considerations, Pearl E. Grimes, MD, Arch 
Dermatol. 1995;131(12):1453-1457. 
3. Development and validation of a health-related quality of life instrument for 
women with melasma. R. Balkrishnan, et.al. Br J Dermatol . 2003;149:572-577. 
  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 23 of 29 
  Version Date: 26Oct16  
 
 
  
 
 
 
 
  
 
 
  
 
 
  
 
  
  
  
  
 
  
 
  
 
 
 
  
  
  
 
  
 
  
 
 
 
 
  
  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 24 of 29 
  Version Date: 26Oct16   
  
 
  
 
 
  
  
  
 
  
 
 
 
 
. 
 
                         
 
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 25 of 29 
  Version Date: 26Oct16  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol: SKM16-LYT-MEL                                                                                                Sponsor:  SkinMedica, Inc.  
Page 26 of 29 
    Version Date: 26Oct16
 

Protocol: SKM16-LYT-MEL                                                                                                Sponsor:  SkinMedica, Inc.  
¬†
Page 27 of 29 
    Version Date: 26Oct16 

Protocol: SKM16-LYT-MEL                                                                                                Sponsor:  SkinMedica, Inc.  
¬†
Page 28 of 29 
    Version Date: 26Oct16 

Protocol: SKM16-LYT-MEL                                                                                                Sponsor:  SkinMedica, Inc.  
¬†
Page 29 of 29 
    Version Date: 26Oct16  
 
     
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 1 of 31 
  Version Date: 10Aug16  
Randomized, Double-blinded, Split-face Study comparing the 
Cosmetic Efficacy and Tolerability of Two Topical Products 
in Subjects with Moderate Facial Melasma 
 
PROTOCOL NUMBER:  SKM16-LYT-MEL 
 
 
FUNDING SPONSOR:   SkinMedica Inc., an Allergan Company 
2525 Dupont Drive  
Irvine, CA 92612 
        
  
PRINCIPAL INVESTIGATOR:   
           
      
 
 
      
 
PROTOCOL DATE:  10/Aug/2016 
  
 
 
The study will be conducted according to  the protocol and in compliance with 
International Conferen
ce of Harmonisation Good Clinical Practice Guidelines and all 
other applicable regulat ory requirements. 
 
CONFIDENTIALITY STATEMENT 
THE INFORMATION PROVIDED  IN THIS STUDY PROTOC OL IS INTENDED FOR 
REVIEW BY THE PRINCIPAL INVESTIGATOR, ALL RESEARCH RELATED 
PERSONNEL, ETHICS COMMITTEE(S)  AND HEALTH AUTHORITIES. 
INFORMATION PROVIDED AND CAPTURED IN THIS PROTOCOL  IS STRICTLY 
CONFIDENTIAL AND WILL ONLY BE DISCLOSED WITH WRITTEN CONSENT 
FROM THE SPONSORS. 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 3 of 31 
  Version Date: 10Aug16 Table of Contents 
STUDY SYNOPSIS ................................................................................................................ ... 5 
1.0  BACKGROUND ............................................................................................................... ... 5 
2.0  STUDY OBJECTIVE ..........................................................................................................  6 
3.0  STUDY POPULATION ....................................................................................................... 6  
3.1 Inclusion Criteria ........................................................................................................ ...... 6 
3.2 Exclusion Criteria ........................................................................................................ ..... 7 
4.0  METHODS AND MATERIALS ........................................................................................... 8 
4.2 Study Products ............................................................................................................ .... 9 
4.3 Subject Compliance ....................................................................................................... 10 
4.4 Concomitant Medications .............................................................................................. 10 
4.5 Treatment Group Randomization .................................................................................. 10 
 
6.0 ASSESSMENTS ...............................................................................................................  13 
6.1 Clinical Grading of Efficacy Parameters ........................................................................ 13 
6.2 Investigator‚Äôs Tolerability Assessment ........................................................................... 16 
6.3 Self-Assessment By Questionnaire ............................................................................... 16 6.4 Imaging Procedures ....................................................................................................... 16 
7.0  STATISTICS ............................................................................................................... ...... 17 
8.0 RESPONSIBILITIES OF THE INVESTIGATOR ............................................................... 17 
8.1 Adherence to the Study Protocol ................................................................................... 17 8.2 Data Handling and Record Keeping .............................................................................. 18 
9.0 REGULATORY OBLIGATIONS ........................................................................................ 18 
9.1 Institutional Review Board ............................................................................................. 18  
9.2 Protocol .......................................................................................................................... 18 
9.3 Informed Consent ..........................................................................................................  18 
9.4 Protocol and Informed Consent Changes ...................................................................... 19 9.5 Study Monitoring .......................................................................................................... .. 19 
10.0 CONFIDENTIALITY OF RECORDS ............................................................................... 19 11.0 DELEGATION OF INVESTIGATOR RESPONSIBILITIES.............................................. 20 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 4 of 31 
.  Version Date: 10Aug16 12.0 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS .................................................. 20 
13.0 ADVERSE EVENTS AND REPORTING ......................................................................... 20 
13.1 Serious And/Or Adverse Event Reporting ................................................................... 20 
13.2 Pregnancy During The Study ....................................................................................... 21 
13.3 Anticipated Reactions .................................................................................................. 2 1 
13.4 Unknown/Unforeseeable Risks .................................................................................... 22 13.5 Unblinding ............................................................................................................... ..... 22 
14.0 REFERENCES ............................................................................................................... . 22 
 
 
 
 
  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 5 of 31 
  Version Date: 10Aug16 STUDY SYNOPSIS 
 
Protocol Number  
SKM16-LYT-MEL 
Protocol Title Randomized, Double-blinded, Split -face Study comparing the 
Cosmetic Efficacy and Tolerability of Two Topical Products in 
Subjects with Moderate Facial Melasma  
Study Duration 3 months (12 Weeks) 
Study Population 20 healthy subjects with Fitzpatrick Skin Types III-VI 
Objectives To evaluate and compare the ef ficacy and tolerability of two 
topical products in the impr ovement of facial melasma  
Study Design Single site, investigator-initi ated, double-blinded, parallel arm, 
randomized treatment, split-face,  12-week study comparing the 
efficacy and tolerability of SkinMedica‚Äôs cosmetic topical brightener versus generic hydroqui none 4% topical prescription 
cream. A total of 20 healthy subjects will be enrolled into this study. Subjects will be screened and randomized at Baseline and 
will return for visits at Weeks 4, 8 and 12. The test products will 
be applied only to the affected areas  (dark patches) twice a day, 
morning and evening, every day for 12 weeks. Ancillary products 
will be provided for basic daily skincare regimen use. 
Study Products ÔÇ∑ SkinMedica Facial Cleanser 
ÔÇ∑ SkinMedica Rejuvenative Moisturizer 
ÔÇ∑ SkinMedica Essential Defense Mineral Shield Broad 
Spectrum SPF 35 Sunscreen 
ÔÇ∑ Test Product A (Lytera 2.0) ÔÇ∑ Test Product B (4% Hydroquinone Topical Cream  ) 
Eligibility Criteria Subjects aged 18+ with  
symmetrical moderat e facial melasma.  
 
 
1.0  BACKGROUND 
 
Melasma is a common disorder of hyperpigm entation which typically presents as brown 
or grayish brown macules on the face, in cluding the forehead, malar region, upper lip 
and chin. Melasma is commonly observed in women with Fitzpatrick skin types III to V 
(1), especially Asian and Hispanic women, although all skin types can be affected.   
 Contributing causes of melasma may include ultraviolet irradi ation, oral contraceptives, 
hormone replacement therapy, pregnancy, and thyroid dysfunction (2) however the exact etiology are not yet fully understood.  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 6 of 31 
  Version Date: 10Aug16 Many patients find the uneven skin t one appearance caused by melasma to be 
cosmetically unacceptable.  Finding a succe ssful treatment remains challenging and 
frustrating. Therapies include broad-spectrum sunscreens, hy droquinone, tretinoin, kojic 
acid, alpha hydroxy acids, salicy lic acid, and chemical peels.  
 
The treatment of hyperpigmentation a ssociated with skin aging and melasma is 
challenging due to the prolonge d time to respond and its high relapse rate when therapy 
is discontinued.  Patients are also required to avoid sunlight to improve therapeutic 
results. Hydroquinone is cu rrently the gold standard for the topical treatment of 
hyperpigmentation and melasma. 
 
2.0  STUDY OBJECTIVE 
 
The objective of this study is to evaluate the efficacy and tolerability of SkinMedica‚Äôs 
cosmetic topical brightener versus 4% hydroquinone in the improvement of the 
appearance of moderate facial melasma over the course of 12 weeks. 
 
3.0  STUDY POPULATION 
 
Twenty (20) healthy subjects presenting wit h symmetrical moderate facial melasma, 
who meet all inclusion and exclusion criteria will be eligible to participate in this study. 
 3.1 Inclusion Criteria 
A subject will be eligible to participate if they meet all of the following inclusion 
criteria: 
 
1. Female or male aged 18+ years  
 
 
2. Individuals with symmetrical  (with at least left and right malar region involvement) 
moderate melasma  
 
 
3. Individuals that are willi ng to provide written informed consent and are able to 
read, speak, write, an d understand English.  
 
4. Individuals willing to sign a photography release. 
 
5. Willing to withhold all facial treatments during the course of the study including 
botulinum toxin, injectable fi llers, microdermabrasion, IP L, peels, facials, waxing, 
laser treatments and tightening treatments.  Threading is allowed but not facial 
laser hair removal. 
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 7 of 31 
  Version Date: 10Aug16 6. Willingness to cooperate and participate by  following study requirements  for the 
duration of the study and to report any c hanges in health status  or medications, 
adverse event symptoms, or  reactions immediately. 
 
7. Willingness to not begin using any new co smetic facial make-up during the study. 
If regular users of cosmetic facial make- up, they must have used the product(s) 
without any tolerability issues for at least 2 weeks prior to starting the study. 
 
8. Willingness to avoid as much as possi ble, direct and prolonged sun exposure for 
the duration of the study (including t anning beds), especially from 10 AM to 2 
PM. Subjects are asked to wear protecti ve clothing prior to and during exposure.  
Any extended sun exposure must be recorded in the source documents. 
 
3.2 Exclusion Criteria 
A subject will not be eligible to participat e if they meet an y of the following 
exclusion criteria. 
 
1. Individuals diagnosed with known allergies to study provided skin care products. 
 
2. Individuals who are nu rsing, pregnant, or planning to become pregnant during 
the study according to subject self-report. 
 
3. Individuals with a hi story of skin cancer. 
 
4. Individuals having a health condition and/ or pre-existing or dormant dermatologic 
disease on the face (e.g., psoriasis,  rosacea, acne, eczema, seborrheic 
dermatitis, severe excori ations etc.) that the In vestigator or designee deems 
inappropriate for participation or could in terfere with the outcome of the study. 
 
5. Individuals with a hist ory of immunosuppression/immune deficiency disorders 
(including (HIV infection or AIDS) or currently using immunosuppressive 
medications (e.g., azathioprine, belim umab, cyclophosphamide, Enbrel, Imuran, 
Humira, mycophenolate mofetil, methotre xate, prednisone, Remicade, Stelara.) 
and/or radiation as determined by study doc umentation that the Investigator or 
designee deems inappropriate for participation or could interfere with the 
outcome of the study. 
 
6. Individuals with an uncontro lled disease such as asth ma, diabetes, hypertension, 
hyperthyroidism, or hypothyro idism. Individuals having mu ltiple health conditions 
may be excluded from participatio n even if   the conditions are controlled by diet, 
medication, etc. 
 
7. Individuals with any pl anned surgeries and/or invasive medical procedures during 
the course of the study. 
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 8 of 31 
  Version Date: 10Aug16 8. Individuals who are current ly participating in any other facial usage study or have 
participated in any clinical trial within 4 weeks prior to inclusion into the study. 
 
9. Individuals who have observable suntan, sca rs, nevi, excessive hair, etc. or other 
dermal conditions on the face that might in fluence the test results in the opinion 
of the Investigator or designee. 
 
10. Individuals who start ed hormone replacement therapi es (HRT) or hormones for 
birth control less than 3 months prior to  study entry or who plan on starting, 
stopping, or changing doses of HRT or hormones for birth control during the 
study. 
 
11. Individuals who used any of the following medications or had any of the listed 
procedures within the listed time fram e prior to the study start date: 
ÔÇ∑ Retin-A¬Æ, Retin-A Micro¬Æ, Renova¬Æ , Avita¬Æ, Tazorac¬Æ, Soriatane¬Æ, or 
Differin¬Æ within 4 months 
ÔÇ∑ Had a chemical peel, dermabrasion, non- ablative laser or fractional laser 
resurfacing of the face  and neck within 1 month. 
ÔÇ∑ Accutane¬Æ within 12 months   
ÔÇ∑ Prescription strength ski n lightening products (e.g. hydroquinone, tretinoin, 
AHA, BHA and polyhydroxy acids, 4-hydroxyanisole alone or in 
combination with tretinoin,  etc.) within 3 months 
ÔÇ∑ Any anti-wrinkle, skin lightening produc ts, or any other product or topical 
or systemic medication known to affect  skin aging or dyshcromia (products 
containing alpha/beta/poly-hydroxy ac ids, vitamin C, soy, Q-10, 
hydroquinone; systemic or licorice extr act (topically), Tego¬Æ Cosmo C250, 
gigawhite, lemon juice extract (topical ly), emblica extract, etc.) within 2 
weeks. 
ÔÇ∑ Have undergone a regimen of Therm age treatments or an equivalent type 
of high energy treatments, pl astic surgery, or ablati ve laser resurfacing of 
the face and neck within 12 months 
ÔÇ∑ Had facial treatment with a botulinum toxin base injectable (Botox), 
injectable fillers, or a fat transfer within 6 months. 
 
4.0  METHODS AND MATERIALS 
 
  
  
  
 
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 9 of 31 
  Version Date: 10Aug16   
 
 
 
  
 
  
 
 
 
 
 
 
  
 
 
 
  
 
 
  
 
  
 
4.2 Study Products 
 
SkinMedic
a Facial Cleanser: Water/Aqua/Eau,Disodium Laureth 
Sulfosuccinate,Cocamidopropyl Hydroxysultaine,Sodium Lauryl 
Sulfoacetate,Camellia Oleifera Leaf Extract, Glycerin, Panthenol, Butylene 
Glycol, Ethylhexylglycerin,PEG-150 P entaerythrityl Tetr astearate, PEG-6, 
Caprylic/Capric, Glycerides, Disodium EDTA, Phenoxyethanol, 
Parfum/Fragrance, Blue 1 (C I 42090), Yellow 10 (CI 47005) 
 Test Product A (Cosmetic topical serum ‚ÄúL ytera 2.0‚Äù): Water/ Aqua/Eau, Butylene 
Glycol, Glycerin, Niacinamide, Polyacrylate-13,  Phenylethyl Resorcinol, Tranexamic Acid, Vitis Vinifera (Grape) Flower Cell Extract, Plankton Extract, 
Tetrapeptide-30, Artemisia Capillaris Flower Extract, Vibr io Alginolyticus Ferment 
Filtrate, Alteromonas Ferment Extrac t, Tocopheryl Acetate, Polyisobutene, 
Polysorbate 20, Caprylic/Capric Triglyce ride, Hydroxyacetophenone, Phytic Acid, 
Diethylhexyl Syringylidenemalonate, Disodium EDTA, Ethylhexylglycerin, Phenoxyethanol   SkinMedica Rejuvenative Moisturize r: Water/Aqua/Eau, Caprylic/Capric 
Triglyceride, Tocopheryl Acetate, Digl ycerin, Isostearyl Behenate, Glyceryl 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 10 of 31 
  Version Date: 10Aug16 Stearate, PEG-100 St earate, Tetrahexyldecyl Ascorbate, Butyrospermum Parkii 
Butter, Panthenol, Phytosterols, Tocopher ol, Tocotrienols, Squalene, Oryza 
Sativa Bran Cera, Aloe Barbadensis Leaf Juice, Algae Extract, Bisabolol, Ginkgo 
Biloba Leaf Extract, Avena Sativa Kernel Extract, Sodium Hyaluronate, Stearyl 
Glycyrrhetinate, Retinyl Palmitate, Glyce rin, Glyceryl Polyacrylate, Dimethicone, 
Cetyl Alcohol, Cetearyl Alcohol, Cetear eth-20, Caprylyl Methicone, Carbomer, 
Tromethamine, Disodium EDTA , Po tassium Sorbate, Phenoxyethanol, 
Ethylhexylglycerin, Parfum/Fragrance 
  SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 
Sunscreen: Water, Cyclopentasiloxa ne, Dimethicone, Polyglyceryl-3 
Polydimethylsiloxyethyl Dimethicone, Bu tylene Glycol, Aluminum Hydroxide, 
Dimethicone/PEG-10/15 Crosspolymer , PEG-9 Polydimethylsiloxyethyl 
Dimethicone, Sodium Chloride, Caffeine, Camellia oleifera Leaf Extract, Sodium 
Citrate, Dimethicone/Vinyl Dimethicone Crosspolymer, Triethoxysilylethyl 
Polydimethylsiloxyethyl Hexyl Dimethic one, Stearic Acid, Ethylhexylglycerin, 
Phenoxyethanol  Test Product B (4% Hydroquinone Topical Prescription Cream): 
 [Ingredients TBD depending on Pharmacy] 
 
4.3 Subject Compliance  
Subject compliance to the study treatment r egimen will be verbally assessed; 
study personnel will ask each subject whether they missed any applications of 
study treatment since the previous vi sit and will quantify the subject‚Äôs response.  
 
4.4 Concomitant Medications 
Systemic and topical medications being us ed at baseline that are considered 
necessary for the subject‚Äôs welfare and will not interfere with the study may be 
used.  Administration of these drugs mu st be reported on the appropriate case 
report form and any alterations in the us e of the medication during the study will 
be carefully noted.  Administra tion of a prohibited drug ( see section 4.2 of 
protocol) in an emergency situation is done with the safety of the study 
participant as the prime consideration.  All topical and systemic medications that 
the subject receives during the study will be recorded.  Any alterations will be 
noted. 
  
4.5 Treatment Group Randomization 
Subjects will be randomized in a 1:1 fashion to receive treatment with 
SkinMedica‚Äôs cosmetic topical bright ener or 4% hydroquinon e. A randomization 
table will be provided by the sponsor and used to determine which facial side will 
be treated with Test Product A (cosmetic topical serum ‚ÄúLytera 2.0‚Äù) and Test 
Product B (4% hydroquinone)  for each subject.  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 11 of 31 
  Version Date: 10Aug16 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
Page 12 of 31 
  Version Date: 10Aug16  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 13 of 31 
  Version Date: 10Aug16 6.0 ASSESSMENTS  
6.1 Clinical Grad
ing of Efficacy Parameters  
 
Clinical grading of the efficacy parameter will be performed at t he study visits indicated. 
Hyperpigmentation will be assessed on the left and the right side  of each subject‚Äôs 
face separately. 
 
Melasma Severity Rating Scale: 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 14 of 31 
  Version Date: 10Aug16 At the screening/baseline visit and the end of treatment visit (week 12), the 
Invesgator will assess the subject‚Äôs facial  skin for the severity of symmetrical 
facial melasma using the following Mela sma Severity Rating Scale on the left and 
right facial sides. Subjects must present with a score of 2 for the left and the right 
facial sides to be enrolled into the study. 
   
Score Hyperpigmentation Status 
0 Cleared: color of melasma lesions 
approximately equivalent to 
surrounding normal skin or with minimal residual hyperpigmentation 
1 Mild: color slightly darker than the 
surrounding normal skin 
2 Moderate: color moderately darker 
than the surrounding normal skin 
3 Severe: color markedly darker than 
the surrounding normal skin 
 
 Overall Hyperpigmentation Scale: 
At all visits (baseline, weeks 4, 8 and 12) , the Investigator will globally assess the 
subject‚Äôs left and right facial sides fo r overall hyperpigm entation using the 
following ten point scale (0 ‚Äì 9): 
None  
(Score of 0)  
Skin is normal in color with no evidence of hyperpigmentation  
Mild  
(Score of 1, 2 or 3) Several brown spots with increas ed pigmentation; they are 
small in size and slightly darker than surrounding skin 
Moderate  
(Score of 4, 5 or 6) Many brown spots with increas ed pigmentation; they are 
medium in size and much darker than surrounding skin 
Severe  
(Score of 7, 8 or 9) Many large brown spots with increased pigmentation; they 
are large in size and markedly darker than surrounding skin
 
 
Half-face Evaluation of Melasma Area Severity Index (MASI) Score 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 15 of 31 
  Version Date: 10Aug16 At all visits, (baseline, weeks 4, 8 and 12), the Investigator will assign a grade for 
the left and right facial sides, for each of the below units, for the variable A 
(percentage of each area involved), D (dar kness of pigment) and P (pattern of 
involvement), as described in detail below.   
Calculations will be conducted by the s ponsor upon receipt of the completed 
CRFs. 
3 variables are assessed for each half- facial unit : 
- Total Area Involved ( A) 
- Darkness of pigment ( D)  
- Homogeneity ( H) 
 
Variable Definitions: 
A = A numerical value is assigned for th e corresponding percentage of the 
total area of the facial segment being assessed.   
This value represents ONLY the percent of the area invo lved, not the pattern or 
darkness of the pigment.  
0=  No involvement 
1= <10% involvement 
2= 10-29% involvement 
3= 30-49% involvement 
4= 50-69% involvement 
5= 70-89% involvement 
6= 90-100% involvement  
 
D = Darkness of the pigment compared to adjacent normal pigment.   
0= Normal skin color  
1= Slightly darker than normal color 
2 = Mild hyperpigmentation 
3= Modrate hyperpigmentation,clearl y and distinctly darker than normal 
pigment 
4 = Severe hyperpigmentation, virtually black pigment  
 
H = The homogeneity of the pigmentation will be assessed using the below 
scale:  
0= Normal skin color without evidence of hyperpigmentation 
1= Specks of involvement  
2 = Small patchy areas of in volvement < 1.5 cm diameter   
3 = Patches of involvement> 2 cm diameter   
4 = Uniform skin involvement  without any clear areas  
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 16 of 31 
  Version Date: 10Aug16 Calculation of the hal f-face MASI score:  
To calculate the half-face MASI score, t he sum of the severity grade for darkness 
(D) and homogeneity (H) is multiplied by t he numerical value of the areas (A) 
involved and by the percentages of the four facial areas (10-30%). 
 
Total Half-Face MASI score:  
Half Forehead 0.15(D+H)A + One Mala r Side 0.3 (D+H)A + Half Chin 
0.05(D+H)A 
 
 
Investigator‚Äôs Global Improvement Assessment- Overall 
Hyperpigmentation: 
 
The expert grader will also score an In vestigator‚Äôs Global Improvement 
Assessment for Overall Hyperpigmentation on the left and right facial sides at all 
follow-up visits (weeks 4, 8, and 12). 
0=No change or worsening 
1=Mild improvement (~25% overall improvement) 2=Moderate improvement (~50% overall improvement) 3=Marked improvement (~75%  overall improvement) 
4=Complete clearing/Dramatic improv ement (~95%+ overa ll improvement) 
 
6.2 Investigator‚Äôs Tolerability Assessment 
Tolerability of the test pr oducts will be assessed through the capture of adverse events 
reported throughout the study per iod. Any adverse event(s) ex perienced by the subject 
during the study period, whether  related to the treatment or  not, will be recorded in the 
‚ÄúCase Report Form.‚Äù 
6.3 Subject MELASQOL Assessment  
Subjects will complete the MELASQOL asse ssement regarding the left and their right 
facial sides at the baseline visit and at w eek 12 only. The MELASQOL is a validated 
assessment to help measure t he emotional and psychological im pact of melasma (3).  
This questionnaire is found in .  
 
6.4 Subject Self-Assessment Questionnaires  
Subjects will complete a Sponsor-provided self-assessment questionnaire at follow-up 
visits at weeks 4, 8, and 12. The assessment consists in a personal and subjective evaluation of the facial skin quality during and after the tr eatment by the subject. In 
addition, the assessment serves to evaluate the self-perceiv ed cosmetic efficacy of the 
treatment and the product attributes. This  questionnaire is f ound in  
 6.5 Imaging Procedures 
Photographs will be taken at all visits utilizi
ng standardized conditions for all subjects.  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 17 of 31 
  Version Date: 10Aug16 The skin must be cleansed prior to photography to remove any makeup, including 
foundation makeup, lipstick/ gloss and eye shadow. The settings for the exposure, 
lighting, flash, and focal length will be maintained constant over the course of the study.  
 Ensure that subjects jewelry is remov ed from ears/neck and hair is pushed back away 
from the face, ensuring that no stray hairs are in the facial area. Subjects will be photographed using an appropriate  clinical digital photography system 
 at highest resolution in a 
consistent position. Importantly, the phot ography should be taken to enable comparison 
of baseline photos with later photos taken at the end of the tr eatment period. For 
instance, if available, the overlay functi on must be used. As each photograph is being 
taken, it should be viewed to ensure that it is in focus and is similar to its baseline 
counterpart in all technical aspects, includi ng lighting, distance and angle. In addition, 
the face should be captured in neutral faci al expressions and neutral angles (e.g., 
avoiding hypo- or hyperex tension of the neck).  
 Photos using the  will be taken from three angles to enable the improvement to 
be clearly noticed: full frontal (0 ¬∞) and at profile from the left (45¬∞) and from the right side 
(45¬∞). Photos will be taken at controlled distances under standard room lighting. Cross-polarized, parallel- polarized and visible light images will be acquired along with both blue fluorescence and ultraviolet fluore scence images. During the photography, the 
subjects will be asked to keep their eyes closed. 
 
6.6 Mexameter Instrume ntation Procedures 
Two target hyperpigmented lesi ons will be selected from the left (1) and the right (2) 
malar facial areas and measured by the mexameter, and instrument that measures melanin content. Measurement s at subsequent visits must  be taken from the same 
target lesion locations as at the baseline visit within each subject. 
One target ‚Äúnormal‚Äù measur ement will also be taken from an unaffected skin area on 
the face representing normal skin. The val ues from the target hyperpigmented lesions 
will be compared to the normal lesion value. 
 
7.0  STATISTICS 
Statistical analyses will be c onducted by the sponsor on an in tent-to-treat basis (ex: all 
enrolled subjects, with at least one follow- up visit, will be included in the analysis).   
 
8.0 RESPONSIBILITIES OF THE INVESTIGATOR 
8.1 Adherence to th e Study Protocol 
The Investigator must ensure adherence to  the procedures outlined in this Study 
Protocol.  The procedures set out in this study protocol, pertaining to the conduct, 
evaluation, and documentation of this st udy, are designed to ensure that the 
Investigator abides by GCP as descri bed in the ICH Guidelines Topic E6: 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 18 of 31 
  Version Date: 10Aug16 ‚ÄúGuideline for Good Clinical Practice.‚Äù  Compliance with these regulations also 
constitutes compliance with the ethical prin ciples described in the current revision 
of the Declaration of Helsinki.  The st udy will also be carried out in keeping with 
local legal and regulat ory requirements. 
 
8.2 Data Handling and Record Keeping 
The Investigator must ensure that pr oper source documentation for all study 
activities are diligently maintained and securely kept.  The Investigator will 
transfer all relevant data to the Case Report Form as stipulated in this Study 
Protocol and his/her signature on the Case Report Form guarantees completeness and integrity of these data.  The Investigator will store all study 
related supplies in a secure and locked loca tion. In addition, the Investigator will 
ensure that all Case Report Forms will be maintained for a period of two years 
after the conclusion of the study. 
 
9.0 REGULATORY OBLIGATIONS 
9.1 Institutional Review Board 
The study protocol, informed consent fo rms (all versions), and any specific 
advertising will be submitted to and approved by Independent Investigational 
Review Board before the start of the study.  A form must be signed by the 
chairman or designee of the IRB noting the approvals. This notification will be 
provided to SkinMedica for notif ication of study initiation. 
 
9.2 Protocol 
The Investigator signing the protocol signature page will act as the Principal 
Investigator at this site. Protocols wil l be noted as approved by the Investigator 
by placement of his signature on the Invest igator‚Äôs Signature Page.  Copies of 
the IRB approved protocol and informed consents will be provided to 
SkinMedica. 
 
9.3 Informed Con sent 
An Informed Consent Form (ICF) that in cludes all of the relevant elements 
currently required by FDA or stat e regulations will be provided to each 
prospective study subject at screening and before enrollment into  the study.  The 
type and method of study, any potential or possible hazards, and the subject‚Äôs 
right to withdraw from the study at any time will be explained to the subjects by 
the Investigator or Designee. Once the In vestigator or Designee is assured that 
an individual candidate understands  the implications of participating in this study, 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 19 of 31 
  Version Date: 10Aug16 the subject will be asked to give consent  by signing and dating in the appropriate 
areas of the Informed Consent Form.  The Investigator or Designee will also sign 
and date the ICF.  A copy of the IRB appr oved ICF will be given to the subject for 
the subject‚Äôs records and the original will be filed in the subject‚Äôs binder or folder. 
 
9.4 Protocol and Informed Consent Changes 
Changes to the protocol or Informed Consent Forms will be implemented as amendments to the original document and approved by the IRB.  The approvals 
will be processed in accordance with the established IRB procedures.  Copies of 
all protocol and ICF amendments/revi sions, along with letters noting IRB 
approval, will be submitted to SkinMedica , as this may affect safety.  Any 
addenda, amendment or revision that substantially alte rs the study design or 
increases potential risk to the subjec t will require the subject‚Äôs consent to 
continue in the study. 
 
9.5 Study Monitoring 
The site will be responsible for internal ve rification of complete  and accurate data 
collection and confirming adherence to the protocol throughout the study. The 
study may be monitored by Sponsor repres entatives to ensure that the protocol 
and GCP guidelines are being followed and to assist in resolving any difficulties 
encountered while the study is in progress.  The monitoring may include site visits 
and frequent communications (telephone, fax, email, letters).  
 
10.0 CONFIDENTIALITY OF RECORDS 
 
Information about the subject‚Äô s health taken during this study may be used and given to 
others by the study coordinator s, the medical staff, the res pective study center and by 
the subject‚Äôs doctors and their other healthcare providers. The subject‚Äôs doctors and 
their healthcare providers may share health  information about the subject with the 
investigator and study coordi nator. The study coordinator and the providers may share 
that information with researchers participating in this study‚Äôs laboratories conducting 
tests for this study. A final study report ma y be shared with SkinMedica, Inc.; The U.S. 
Food and Drug Administration (FDA); Depart ment of Health and Human Services 
(DHHS) agencies; other U.S. and foreign government agencies that watch over quality, 
safety and effectiveness of research. 
 
All research related personnel will ensure su bject confidentiality is maintained. All 
subject related documents will be identified by subject initials and subject identification 
numbers. All subject related documents will be filed in individual subject binders or 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 20 of 31 
  Version Date: 10Aug16 folders and stored in confidenc e by the site only to be accessed by research related 
personnel. 
 
11.0 DELEGATION OF INVESTIGATOR RESPONSIBILITIES 
 
The Investigator should ensure that all per sons assisting with the trial are adequately 
informed about the protocol, any amendments to  the protocol, the study treatments, and 
their trial-related duties and functions.  The investigator should maintain a list of sub-
investigators and other appropriately qualif ied persons to whom he has delegated 
significant trial-related duties. 
 
12.0 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS 
 
The Investigator must ensure that institutional regulations , the Informed Consent Form, 
and the HIPAA Authorization clearly permit st udy-related monitoring, audits, IRB review, 
and regulatory inspections providing direct access to source data and documents. 
 
13.0 ADVERSE EVENTS AND REPORTING 
 
13.1 Serious And/Or Adverse Event Reporting 
A serious adverse event is any untoward medical occurrence, that, at any dose: 
ÔÇß results in death; 
ÔÇß is life-threatening; 
ÔÇß requires in-subject hospitalization or pr olongation of existing hospitalization; 
ÔÇß results in persistent or significant disability/incapacity;  
ÔÇß is a congenital anomaly/birth defect; or 
ÔÇß is an important medical event. 
 
Throughout the study, subjec ts will be monitored for signs and symptoms of 
adverse events.  An adverse event is any pathological or unintended change in 
the structure, function or chemistry of the body that  occurs during the study, 
irrespective of causality, including any ill ness, injury, toxicity, sensitivity, or 
sudden death.  The condition must eit her not be present pre-study or must 
worsen in either intensity or frequency during the study. 
 
An unanticipated adverse study drug event is any drug-related adverse event, 
which is not identified in nature, severity , or frequency in current literature on the 
test article.  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 21 of 31 
  Version Date: 10Aug16 All adverse events, including serious and study drug related or unanticipated 
adverse drug events, must be recorded and assessed by th e Investigator.  In the 
event of an adverse event, serious adverse  event or unanticipated adverse drug 
event, the physician will prov ide optimal subject care. 
 
Subjects who have had a serious adverse event must be followed clinically until 
all parameters, including labor atory values, have either returned to normal or are 
otherwise explained. 
 
Any serious adverse event or unanticipat ed adverse drug event occurring in this 
study will be analyzed and identif ied by the investigator and reported to the IRB 
within 10 business days, as per IND regulations and FDA Guidance. The 
investigator will also determine the event re lated to the study drug and report that 
event to the manufacture of the device, if necessary. 
 
Serious adverse events will be reported to the Sponsor within 24 hours (or the 
next working day). The main Sponsor c ontact for serious adverse events is: 
 
If death was the outcome of the event  on the initial SAE Report, a Follow-
up/Final Report, including autopsy report, when performed, must be completed. 
 
13.2 Pregnancy During The Study 
If a subject of childbearing potential becomes pregnant at any time while 
participating during the study, the pregnancy will be deemed an Adverse Event 
and the subject will stop all protocol re lated procedures. The investigator will 
follow-up with the subject until the pregnancy reaches term or until the pregnancy 
has been resolved. 
 
The Investigator will report the Adverse Event of pregnancy to the IRB within 24 
hours of awareness of the event and follow-up reports will be filed with the IRB 
as information with changes of t he pregnancy becomes available. 
 
13.3 Anticipated Reactions 
All test materials have the potential to cause some minor side-effects or other 
reactions. Possible reactions to the test  material(s) may include (but are not 
limited to) subjective sensations (such as itching, burning, stinging, tingling), 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 22 of 31 
  Version Date: 10Aug16 scaling/dryness, and redness. Additionally, test materi al(s) applied to the eye 
areas have the potential to cause eye wa tering/tearing, redness of the eyes, 
corneal erosions, and foreign body sensation in the eyes.  
 Symptoms of mild to moderate irritation, including the examples discussed above, will not be treated as adverse reactions if they are mild in nature. These 
conditions may or may not resolve over ti me. Symptoms that are persistent and 
moderate to severe in natur e, or that involve elevat ion (e.g. edema, papules, 
vesicles, spreading) wil l be considered AEs.  
In rare cases, it is possible for a subject to develop allergic reactions to the test 
material(s). This risk is increased for individuals with a histor y of allergies, and 
individuals with asthma and/or  a history of hives may al so be affected. Subjects 
will be instructed to notify the clinic imm ediately if they experience an allergic 
reaction including rash, hives, and itching.  The Investigator or designee will have the final authorization to determine if a reaction will be c onsidered an AE.  
 
13.4 Unknown/Unforeseeable Risks 
In addition to the risks listed above, t here may be some unknown or infrequent 
and unforeseeable risks associated with the use of the assigned study products. 
Subjects will be informed both verbally and in writing in  a timely manner of any 
new information, findings or changes to the way the research will be performed that might influence their willingness to cont inue their participation in this study. 
 Pregnancy/Fetal Risks:  The effects of SkinMedica Facial Cleanser, Rejuvenative Moisturizer, Essential Defense Mineral Shield Broad Spectrum SPF 35, Test 
Product A (Lytera 2.0) and Test Produc t B (4% Hydroquinone) have not been 
studied in pregnancy and theref ore may be hazardous.   
 If a subject thinks that she may be pr egnant or have become pregnant during the 
study she is to inform the study doctor immediately. If a subject becomes pregnant or thinks they may be pregnant, t hey will be removed from the study 
and the study doctor will refer the subject to seek obstetric care and may request 
to track their pregnancy and will report  to the IRB. 
 
13.5 Unblinding 
In the event that a subject experiences  an Adverse Event or Serious Adverse 
Event, the Investigator and/or S ub-Investigator will become unblinded. 
 
14.0 REFERENCES 
1. Melasma: a clinical and epidemiologi cal review* Ana Carolina Handel, Luciane 
Donida Bartoli Miot, and H√©lio Amante Mio t, An Bras Dermatol. 2014 Sep-Oct; 
89(5): 771‚Äì782. 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 23 of 31 
  Version Date: 10Aug16 2. Melasma. Etiologic and Therapeutic Considerations, Pearl E. Grimes, MD, Arch 
Dermatol. 1995;131(12):1453-1457. 
3. Development and validation of a health-related quality of life instrument for 
women with melasma. R. Balkrishnan, et.al. Br J Dermatol . 2003;149:572-577. 
  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 24 of 31 
  Version Date: 10Aug16  
 
 
  
 
 
 
 
  
 
 
  
 
 
  
 
  
  
  
  
 
  
 
  
  
 
 
  
  
  
 
  
 
  
  
 
 
 
  
  

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 25 of 31 
  Version Date: 10Aug16   
  
 
  
 
 
  
  
  
 
  
 
 
 
 
 
                          
 

Protocol: SKM16-LYT-MEL                           Sponsor: SkinMedica, Inc.  
¬†
Page 26 of 31 
  Version Date: 10Aug16  
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol: SKM16-LYT-MEL                                                                                                Sponsor:  SkinMedica, Inc.  
¬†
Page 27 of 31 
     Version Date:  

Protocol: SKM16-LYT-MEL                                                                                                Sponsor:  SkinMedica, Inc.  
¬†
Page 28 of 31 
     Version Date:  

Protocol: SKM16-LYT-MEL                                                                                                Sponsor:  SkinMedica, Inc.  
Page 29 of 31 
     Version Date:  

Protocol: SKM16-LYT-MEL                                                                                                Sponsor:  SkinMedica, Inc.  
¬†
Page 30 of 31 
     Version Date:   
  
 
              

Protocol: SKM16-LYT-MEL                                                                                                Sponsor:  SkinMedica, Inc.  
¬†
Page 31 of 31 
     Version Date:   
